Patients

At Cartesian, our commitment to patients
is at the heart of everything we do.

We recognize that many people may already be familiar with cell therapy. Currently existing cell therapies typically require patients to undergo pretreatment chemotherapy and are administered in the inpatient setting, resulting in challenges related to toxicity, complexity, and cost. At Cartesian, our mRNA cell therapy candidates are purposefully designed to be dosed in an outpatient setting without pretreatment chemotherapy. Learn more about our unique approach.

With this patient-centric approach, we aim to improve outcomes, enhance quality of life, and empower patients to live healthier, fuller lives. Working in close collaboration with healthcare professionals, patient communities, and advocates, we are steadfast in our mission to expand the reach of cell therapy for the treatment of autoimmune diseases.

Clinical Trials

We are currently conducting several clinical trials
evaluating our mRNA cell therapy candidates.

Patient Resources

Generalized Myasthenia Gravis:
Systemic Lupus Erythematosus: